Lupin Launches Global Partnership Program for Its PrecisionSphere LAI Platform

Lupin Limited has announced the launch of a strategic partnership program to expand the reach of its long-acting injectable (LAI) platform – PrecisionSphere, developed by its subsidiary Nanomi B.V. The initiative aims to collaborate with global pharma companies seeking to extend drug life cycles through advanced long-acting formulations. Key Highlights FDA-approved platform: PrecisionSphere’s first product recently received U.S. FDA approval, validating its efficacy, safety, and scalability. Enhanced performance: Ensures consistent particle size, shape, and injectability, improving drug stability and patient adherence. Collaboration focus: Lupin offers regulatory expertise, flexible partnership models, and manufacturing excellence to accelerate LAI innovation. Global reach: The program supports broader patient access to next-gen treatments across therapeutic areas worldwide. Lupin, present in 100+ markets with diversified therapy expertise, continues to drive healthcare innovation through science-led partnerships and advanced drug delivery platforms. ✅ Disclaimer: This update is for informational purposes only and not investment advice. 👉 Follow for more corporate and healthcare innovation updates.